MetaCap

Addex Therapeutics (ADXN) vs FibroBiologics (FBLG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

FibroBiologics is the larger company by market cap ($6.3 million vs $6.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADXN+10.86%FBLG-38.16%
+74%+15%-44%
Oct 7, 20261 yearNov 20, 2026
ADXN+7.81%FBLG-37.61%
+29%-6%-41%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADXN versus FBLG key metrics
MetricADXNFBLG
Share price$3.47$0.705
Market cap$6.08M$6.34M
1-day change+2.06%-15.06%
EPS (TTM)$-7.56$-2.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-18.65M
52-week high$10.43$9.60
52-week low$2.56$0.62
Distance from 52-week high-66.73%-92.66%
Analyst consensus—none
Avg. price target upside—+1673.05%
Average volume383.35K160.05K
Shares outstanding1.75M8.99M
Employees315
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Addex Therapeutics

ADXN stock →

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About FibroBiologics

FBLG stock →

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ADXN vs FBLG FAQ

Which is bigger, Addex Therapeutics or FibroBiologics?

FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.08M for Addex Therapeutics (ADXN).

Are Addex Therapeutics and FibroBiologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons